The Endocannabinoid System as a Therapeutic Target in Diabetic Peripheral Neuropathic Pain: A Review
Abstract Diabetic peripheral neuropathy (DPN) is characterized by progressive loss of peripheral nerves, which causes numbness, weakness, and severe pain. The medications available currently provide only modest relief from the pain of DPN and are associated with various side effects, which has generated an enormous demand for research on new therapeutic approaches. Dysregulation of the endocannabinoid system has been reported in DPN. Cannabinoid-based medications have gained increasing attention as a potential therapy to alleviate DPN pain. Endocannabinoids and cannabinoids’ actions
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join — it's freeAlready a member? Log in
